Investors

Corporate Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Download Corporate Presentation
Aurinia Corporate Presentation November 2025
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable U.S. securities law and forward-looking information within the meaning of applicable Canadian securities law.
Changing the Trajectory of Autoimmune Diseases
Recent Financial Results
Results for the Three Months Ended September 30
Results for the Nine Months Ended September 30
Cash Flows and Financial Position
2025 Financial Guidance
LUPKYNIS® – A calcineurin inhibitor (CNI) indicated in combination with a background immunosuppressive regimen for the treatment of adult patients with active lupus nephritis. The first oral therapy approved for the treatment of lupus nephritis
Lupus Nephritis (LN) Is Among the Most Severe and Dangerous Complications of Systematic Lupus Erythematosus (SLE)
Proteinuria Reduction Is Associated with Long-Term Renal Preservation
Recent American College of Rheumatology (ACR)Lupus Nephritis Treatment Guideline Update
LUPKYNIS Is a Novel, Structurally Modified CNI that Targets LN with a Dual Mechanism of Action
Robust Clinical Study History
Significantly More Patients on LUPKYNIS Achieved a Complete Renal Response in AURORA 1 as Early as Week 24
LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1
New Analysis Shows LUPKYNIS Associated with 53% Reduction in Risk of Renal-Related Event or Death
Adverse Reactions Occurring in ≥3% of Patients Treated with LUPKYNIS 23.7 mg Twice a Day and ≥2% Higher than Placebo in AURORA 1 and AURA-LV
Aritinercept – A dual BAFF/APRIL inhibitor for the potential treatment of autoimmune diseases
Aritinercept Is a Dual BAFF/APRIL Inhibitor
Role of BAFF and APRIL
Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor
Aritinercept Potently Inhibits BAFF-and APRIL-Mediated B Cell Proliferation
Aritinercept Single Ascending Dose (SAD) Study: Design
Aritinercept SAD Study:Safety Summary
Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins in Humans
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG
Summary and Next Steps
Aurinia Pharmaceuticals Inc., 2025. All rights reserved.

Email Alerts

By providing your email address above, you are providing consent to Aurinia Pharmaceuticals Inc. to send you the requested Investor Email Alert updates. For information on how we protect your information, please refer to our Privacy Policy.
Thank you. Your request has been received.
Oops! There was an error with your submission.

Stock Information

NASDAQ Global Market: AUPH

$14.27

+1.10

/

+8.35%

5.03M

Volume

Last update:
Closed at 11/04/2025 4:00PM ET
Pricing delayed by 15 minutes

Upcoming Events

There are no upcoming events scheduled at this time.

Past Events

Select Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 19
-
May 19, 2020
May 19, 2020 10:20 AM
EDT
2020

RBC 2020 Virtual Healthcare Global Conference

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
May 14
-
May 14, 2020
May 14, 2020 4:30 PM
EDT
2020

First Quarter 2020 Financial Results Conference Call

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Mar 26
-
Mar 26, 2020
Mar 26, 2020 4:15 PM
CDT
2020

National Kidney Foundation 2020 Spring Clinical Meetings

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Mar 5
-
Mar 5, 2020
Mar 5, 2020 4:30 PM
EDT
2020

Fourth Quarter and Full Year 2019 Financial Results Conference Call

Press Release40-FWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
Feb 25
-
Feb 25, 2020
Feb 25, 2020 10:00 AM
EDT
2020

9th Annual SVB Leerink Global Healthcare Conference

Press ReleaseWebcastPresentationFinancials and MDA - IFRSFinancials - US GAAPFinancials and MDA
No Results Found
Please try different keywords or filters.

SEC Filings

Select Year
Form Types
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Date
Filing Type
Description
Download
Date
March 2, 2017
2017
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
March 1, 2017
2017
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
February 24, 2017
2017
Filing Type
SUPPL
Description
Voluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuers
Other
Download
Date
February 16, 2017
2017
Filing Type
6-K
Description
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Current Reports
Download
Date
February 14, 2017
2017
Filing Type
SC 13G/A
Description
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
Section 16 Filings
Download
No Results Found
Please try different keywords or filters.

Governance

Committee Charter Documents
Audit Committee Charter
Download
Compensation Committee Charter
Download
Corporate Governance Committee Charter
Download
Disclosure Committee Charter
Download
Governance Documents
Anti-Fraud Policy
Articles
Certificate and Articles of Amendment
Certificate of Amalgamation
Code of Ethics and Conduct
Conformed By-Law No. 2
Corporate Disclosure Policy
Forced Labour Report
Indemnity Policy
Information for Vermont Prescribers
Insider Trading Policy
Majority Voting Policy
Mandate of the Board of Directors
Position Description - CFO
Position Description - President - CEO
Terms of Reference - Chairman
Whistleblower Policy

IR Contact

General inquiries can be sent to ir@auriniapharma.com